In vivo, FADU tumors were imaged with [89Zr]-pertuzumab (HER2) and [89Zr]-panitumumab (EGFR) (Fig. 2A,C) and heterogeneity (as shown with histogram of the SUV of all tumor voxels) of uptake was quantified. Here, EGFR is linked to neoplasm.